Homology Medicines Inc Received its Third Buy in a Row


After Merrill Lynch and BTIG gave Homology Medicines Inc (NASDAQ: FIXX) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Phil Nadeau maintained a Buy rating on Homology Medicines Inc yesterday. The company’s shares closed yesterday at $19.43.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.9% and a 53.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.

Homology Medicines Inc has an analyst consensus of Strong Buy, with a price target consensus of $31.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.40 and a one-year low of $16.12. Currently, Homology Medicines Inc has an average volume of 166.3K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FIXX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts